NIHR Academic Clinical Fellow & Rheumatology Registrar, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, Windmill Road, Oxford, OX3 7HD, UK.
The Medical Sciences Division, University of Oxford, Oxford, UK.
Best Pract Res Clin Rheumatol. 2021 Jun;35(2):101680. doi: 10.1016/j.berh.2021.101680. Epub 2021 Apr 3.
The aims of treatment for psoriatic arthritis (PsA) are to control inflammation, normalise functions and impacts on patients and prevent complications of the disease and its treatment. Over the past decade, treatment options for PsA have expanded with the availability of many more novel therapeutic agents. However, the treatment decisions and pathways for the use of these drugs are not always straightforward. There is a need to tailor the choice of medication to the individual patient, taking into account the type of their disease and consideration of other factors such as their co-morbidities. A treat to target approach is recommended with the aim to get the patient into a state of remission or low disease activity (whichever target is chosen). Both European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR) have recently published updated guidance in 2018-2019. In this section, we will summarise the evidence for therapies in PsA and review the similarities and differences in these two sets of recommendations.
治疗银屑病关节炎 (PsA) 的目的是控制炎症，使患者的功能和影响恢复正常，预防疾病及其治疗的并发症。在过去的十年中，随着更多新型治疗药物的出现，PsA 的治疗选择已经扩大。然而，这些药物的使用决策和途径并不总是那么简单。需要根据患者的个体情况来选择药物，考虑到他们疾病的类型以及其他因素，如合并症。建议采用靶向治疗方法，以使患者达到缓解或低疾病活动状态（无论选择哪个目标）。欧洲抗风湿病联盟 (EULAR) 和美国风湿病学会 (ACR) 都在 2018-2019 年发布了最新的更新指南。在本节中，我们将总结 PsA 治疗的证据，并回顾这两套建议的相似点和不同点。
